MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo.

Understanding mechanisms of autoimmunity through translational research in vitiligo. Curr Opin Immunol (2016) 0.86

Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. Nat Genet (2016) 0.77

Recent advances in understanding vitiligo. F1000Res (2016) 0.75

Genetics of Vitiligo. Dermatol Clin (2017) 0.75

Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A (2010) 15.13

Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol (2003) 12.34

HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res (2011) 11.03

Integrative analysis of 111 reference human epigenomes. Nature (2015) 10.32

Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science (2015) 9.92

Gene map of the extended human MHC. Nat Rev Genet (2004) 6.01

Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol (1997) 5.94

T cell activation determined by T cell receptor number and tunable thresholds. Science (1996) 5.51

Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature (2014) 5.22

Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors. Genome Res (2012) 4.80

Defining functional DNA elements in the human genome. Proc Natl Acad Sci U S A (2014) 3.35

Influence of HLA-C expression level on HIV control. Science (2013) 3.27

Predictive chromatin signatures in the mammalian genome. Hum Mol Genet (2009) 3.25

Transcriptional enhancers: from properties to genome-wide predictions. Nat Rev Genet (2014) 3.16

Autoimmune disease: why and where it occurs. Nat Med (2001) 3.04

Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med (1987) 3.03

The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet (2009) 2.73

High-resolution, high-throughput HLA genotyping by next-generation sequencing. Tissue Antigens (2009) 2.64

Partitioning heritability of regulatory and cell-type-specific variants across 11 common diseases. Am J Hum Genet (2014) 2.53

Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med (2010) 2.47

Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat Genet (2015) 2.05

A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin. J Invest Dermatol (2012) 2.05

Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet (2012) 1.81

A multi-site study using high-resolution HLA genotyping by next generation sequencing. Tissue Antigens (2011) 1.81

High HLA-DP Expression and Graft-versus-Host Disease. N Engl J Med (2015) 1.74

HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation. Blood (2014) 1.63

A direct role for IFN-gamma in regulation of Th1 cell development. J Immunol (1996) 1.56

Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res (2012) 1.48

Peripheral T cell survival. Curr Opin Immunol (1999) 1.42

Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol (2009) 1.34

Common variants in FOXP1 are associated with generalized vitiligo. Nat Genet (2010) 1.25

A novel variant marking HLA-DP expression levels predicts recovery from hepatitis B virus infection. J Virol (2012) 1.24

The minimal number of antigen-major histocompatibility complex class II complexes required for activation of naive and primed T cells. Eur J Immunol (1997) 1.14

NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1β processing via the NLRP1 inflammasome. Proc Natl Acad Sci U S A (2013) 1.12

Treatment of generalized vitiligo with anti-TNF-α Agents. J Drugs Dermatol (2012) 1.08

The role of endogenous interleukin (IL)-18, IL-12, IL-1beta, and tumor necrosis factor-alpha in the production of interferon-gamma induced by Candida albicans in human whole-blood cultures. J Infect Dis (2002) 1.04

Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford) (2015) 1.01

Relationship between HLA-DR gene polymorphisms and outcomes of hepatitis B viral infections: a meta-analysis. World J Gastroenterol (2012) 0.96

DNA methylation dysregulates and silences the HLA-DQ locus by altering chromatin architecture. Genes Immun (2011) 0.91

Worsening of vitiligo and onset of new psoriasiform dermatitis following treatment with infliximab. J Cutan Med Surg (2011) 0.90

Deterioration of vitiligo and new onset of halo naevi observed in two patients receiving adalimumab. Dermatol Ther (2013) 0.90

Segmental vitiligo after infliximab use for rheumatoid arthritis--a case report. An Bras Dermatol (2014) 0.78

Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A*02:01 in vivo. Proc Natl Acad Sci U S A (2016) 0.79